776 related articles for article (PubMed ID: 19950889)
1. Heparin-paclitaxel conjugates as drug delivery system: synthesis, self-assembly property, drug release, and antitumor activity.
Wang Y; Xin D; Liu K; Zhu M; Xiang J
Bioconjug Chem; 2009 Dec; 20(12):2214-21. PubMed ID: 19950889
[TBL] [Abstract][Full Text] [Related]
2. Heparin-paclitaxel conjugates using mixed anhydride as intermediate: synthesis, influence of polymer structure on drug release, anticoagulant activity and in vitro efficiency.
Wang Y; Xin D; Liu K; Xiang J
Pharm Res; 2009 Apr; 26(4):785-93. PubMed ID: 19015960
[TBL] [Abstract][Full Text] [Related]
3. New Taxol (paclitaxel) prodrugs designed for ADEPT and PMT strategies in cancer chemotherapy.
Alaoui AE; Saha N; Schmidt F; Monneret C; Florent JC
Bioorg Med Chem; 2006 Jul; 14(14):5012-9. PubMed ID: 16554162
[TBL] [Abstract][Full Text] [Related]
4. Characterization and preparation of core-shell type nanoparticle for encapsulation of anticancer drug.
Jang MK; Jeong YI; Nah JW
Colloids Surf B Biointerfaces; 2010 Dec; 81(2):530-6. PubMed ID: 20801624
[TBL] [Abstract][Full Text] [Related]
5. Target-specific cellular uptake of taxol-loaded heparin-PEG-folate nanoparticles.
Wang Y; Wang Y; Xiang J; Yao K
Biomacromolecules; 2010 Dec; 11(12):3531-8. PubMed ID: 21086982
[TBL] [Abstract][Full Text] [Related]
6. Drug delivery systems: water soluble taxol 2'-poly(ethylene glycol) ester prodrugs-design and in vivo effectiveness.
Greenwald RB; Gilbert CW; Pendri A; Conover CD; Xia J; Martinez A
J Med Chem; 1996 Jan; 39(2):424-31. PubMed ID: 8558510
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activity of hydrophilic Paclitaxel copolymer prodrug using locoregional delivery in human orthotopic non-small cell lung cancer xenograft models.
Zou Y; Fu H; Ghosh S; Farquhar D; Klostergaard J
Clin Cancer Res; 2004 Nov; 10(21):7382-91. PubMed ID: 15534115
[TBL] [Abstract][Full Text] [Related]
8. Modulating paclitaxel bioavailability for targeting prostate cancer.
Kumar SK; Williams SA; Isaacs JT; Denmeade SR; Khan SR
Bioorg Med Chem; 2007 Jul; 15(14):4973-84. PubMed ID: 17502149
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and biological activity of protaxols.
Nicolaou KC; Riemer C; Kerr MA; Rideout D; Wrasidlo W
Nature; 1993 Jul; 364(6436):464-6. PubMed ID: 8101355
[TBL] [Abstract][Full Text] [Related]
10. Self-assembled silk sericin/poloxamer nanoparticles as nanocarriers of hydrophobic and hydrophilic drugs for targeted delivery.
Mandal BB; Kundu SC
Nanotechnology; 2009 Sep; 20(35):355101. PubMed ID: 19671963
[TBL] [Abstract][Full Text] [Related]
11. Multifunctional pluronic/poly(ethylenimine) nanoparticles for anticancer drug.
Li N; Yang X; Zhai G; Li L
J Colloid Interface Sci; 2010 Oct; 350(1):117-25. PubMed ID: 20598703
[TBL] [Abstract][Full Text] [Related]
12. The use of amino acid linkers in the conjugation of paclitaxel with hyaluronic acid as drug delivery system: synthesis, self-assembled property, drug release, and in vitro efficiency.
Xin D; Wang Y; Xiang J
Pharm Res; 2010 Feb; 27(2):380-9. PubMed ID: 19876721
[TBL] [Abstract][Full Text] [Related]
13. Targeting the delivery of glycan-based paclitaxel prodrugs to cancer cells via glucose transporters.
Lin YS; Tungpradit R; Sinchaikul S; An FM; Liu DZ; Phutrakul S; Chen ST
J Med Chem; 2008 Dec; 51(23):7428-41. PubMed ID: 19053781
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and biological evaluation of paclitaxel-C225 conjugate as a model for targeted drug delivery.
Safavy A; Bonner JA; Waksal HW; Buchsbaum DJ; Gillespie GY; Khazaeli MB; Arani R; Chen DT; Carpenter M; Raisch KP
Bioconjug Chem; 2003; 14(2):302-10. PubMed ID: 12643740
[TBL] [Abstract][Full Text] [Related]
15. Enhanced drug loading on magnetic nanoparticles by layer-by-layer assembly using drug conjugates: blood compatibility evaluation and targeted drug delivery in cancer cells.
Manju S; Sreenivasan K
Langmuir; 2011 Dec; 27(23):14489-96. PubMed ID: 21988497
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and biological evaluation of 2'-carbamate-linked and 2'-carbonate-linked prodrugs of paclitaxel: selective activation by the tumor-associated protease plasmin.
de Groot FM; van Berkom LW; Scheeren HW
J Med Chem; 2000 Aug; 43(16):3093-102. PubMed ID: 10956217
[TBL] [Abstract][Full Text] [Related]
17. Novel isoprenoyl nanoassembled prodrug for paclitaxel delivery.
Mura S; Zouhiri F; Lerondel S; Maksimenko A; Mougin J; Gueutin C; Brambilla D; Caron J; Sliwinski E; Lepape A; Desmaele D; Couvreur P
Bioconjug Chem; 2013 Nov; 24(11):1840-9. PubMed ID: 24134705
[TBL] [Abstract][Full Text] [Related]
18. Paclitaxel-loaded poly(gamma-glutamic acid)-poly(lactide) nanoparticles as a targeted drug delivery system for the treatment of liver cancer.
Liang HF; Chen CT; Chen SC; Kulkarni AR; Chiu YL; Chen MC; Sung HW
Biomaterials; 2006 Mar; 27(9):2051-9. PubMed ID: 16307794
[TBL] [Abstract][Full Text] [Related]
19. Camptothecin delivery systems: the utility of amino acid spacers for the conjugation of camptothecin with polyethylene glycol to create prodrugs.
Conover CD; Greenwald RB; Pendri A; Shum KL
Anticancer Drug Des; 1999 Dec; 14(6):499-506. PubMed ID: 10834271
[TBL] [Abstract][Full Text] [Related]
20. Modulating the therapeutic activity of nanoparticle delivered paclitaxel by manipulating the hydrophobicity of prodrug conjugates.
Ansell SM; Johnstone SA; Tardi PG; Lo L; Xie S; Shu Y; Harasym TO; Harasym NL; Williams L; Bermudes D; Liboiron BD; Saad W; Prud'homme RK; Mayer LD
J Med Chem; 2008 Jun; 51(11):3288-96. PubMed ID: 18465845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
